Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-105081
Filing Date
2025-08-07
Accepted
2025-08-07 16:25:08
Documents
76
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q whwk-20250630.htm   iXBRL 10-Q 3220708
2 EX-31.1 whwk-ex31_1.htm EX-31.1 16902
3 EX-31.2 whwk-ex31_2.htm EX-31.2 16880
4 EX-32.1 whwk-ex32_1.htm EX-32.1 9283
5 EX-32.2 whwk-ex32_2.htm EX-32.2 9269
  Complete submission text file 0000950170-25-105081.txt   12346250

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT whwk-20250630.xsd EX-101.SCH 1314734
79 EXTRACTED XBRL INSTANCE DOCUMENT whwk-20250630_htm.xml XML 2553534
Mailing Address 2 HEADQUARTERS PLAZA EAST BUILDING, 11TH FLOOR MORRISTOWN NJ 07960
Business Address 2 HEADQUARTERS PLAZA EAST BUILDING, 11TH FLOOR MORRISTOWN NJ 07960 551-321-2234
Whitehawk Therapeutics, Inc. (Filer) CIK: 0001422142 (see all company filings)

EIN.: 611547850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38560 | Film No.: 251194507
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)